CTLA4 and melanoma: Indeed, there is an association between pre-treatment Foxp3+ T-reg infiltration, followed by a subsequent increase in TILs 3 weeks into treatment in melanoma biopsies which was associated with response to the CTLA4-targeting antibody ipilimumab (48).